期刊文献+

临床药师参与1例血液透析导管相关性感染患者的治疗实践

Analysis of Clinical Pharmacists Participating in Drug Treatment for a Hemodialysis Patient with conduit Infections
下载PDF
导出
摘要 目的:从药学角度探讨临床药师在参与1例血液透析导管相关性感染患者中的作用.方法:临床药师分析患者感染来源,并结合患者症状、微生物学检查结果选用万古霉素,同时根据患者血液透析方式及万古霉素特性选择用法用量.结果:患者在8~10天体温明显下降,第10日降钙素原(PCT)降为0.7ng/mL,监测万古霉素血药浓度为18.7mg/mL,可继续维持临床药师推荐用法继续治疗.结论:临床药师参与患者抗感染方案的制定,能从专业角度给予医师和患者良好的药学服务. Object: To investigate the strategies of clinical pharmacists participating in drug treatment for hemodialysis patients.Methods: Clinical pharmacists analyzed the infection resources, and selected vancomycin on the basis of symptom and the result of microbiological examination, and constitute the dose of vancomycinon on the basis of pattern of hemodialysis.Results: The patient's temperature decreased significantly in 8 ~ 10 days. On the tenth day, procalcitonin (PCT)reduced to 0.7ng/ml, serum concentration of vancomycin was 18.7mg/ml, which can be continued to maintain the recommended use by clinical pharmacists.Conclusion: Clinical pharmacists can offer better service for doctor and patient.
作者 张帆 宋沧桑
出处 《药品评价》 CAS 2015年第22期35-36,43,共3页 Drug Evaluation
关键词 临床药师 血液透析 感染 万古霉素 Clinical Pharmacist Hemodialysis Infection Vancomycin
  • 相关文献

参考文献6

  • 1Malhotra V, Beniwal P, Pursnani L. Infections in chronic kidney disease[J]. Clinical Queries: Nephrology I, 2012: 253-258.
  • 2孙晓萌,刘宏,刘必成.血管通路感染的诊治进展[J].中国血液净化,2013,12(6):333-336. 被引量:9
  • 3王质刚.液净化学[M].第3版北京:科学技术出版社,2010:1532-1541.
  • 4Pallotta KE, Manley HJ. Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial, 2008,21:63-70.
  • 5Ariano RE, Fine A, Sitar DS, et al. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis[J]. Am J Kidney Dis, 2005,46:681-687.
  • 6万古霉素临床应用剂量中国专家共识[J].中华传染病杂志,2012,30(11):641-646. 被引量:293

二级参考文献36

  • 1Rocklin MA, Dwight CA, Callen LJ, et al. Comparison of cuffed tunneled hemodialysis catheter survival[Jl. Am J Kidney Dis, 2001, 37: 557-63.
  • 2Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and man?agement[Jl. Lancet Infect Dis, 2007, 7: 645-57.
  • 3Akoh JA. Vascular access infections: epidemiology, diagnosis, and management[Jl. Curr Infect Dis Rep, 2011, 13: 324-32.
  • 4Jean G, Charra B, Chazot C, et al. Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias[Jl. Nephron, 2002, 91: 399-405.
  • 5Costerton lW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science[J]. 1999, 284: 1318-1322.
  • 6Donlan RM, Costerton lW. Biofilms: survival mechanisms of clinically relevant microorganisms[J]. Clin Microbiol Rev. 2002, 15: 167-193.
  • 7Sanders J, Pithie A, Ganly P, et al. A prospective double?blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associ?ated bloodstream infection in immunosuppressed haematology patients[J]. J Antimicrob Chemother, 2008, 62: 809-815.
  • 8Walters MC 3rd, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low meta?bolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin[J]. Antimicrob Agents Chemother, 2003, 47: 317-323.
  • 9Xavier JB, Foster KR. Cooperation and conflict in micro?bial biofilms[J]. Proc Natl Acad Sci USA, 2007, 104: 876- 81.
  • 10del PJL, Patel R. The challenge of treating biofilm-asso?ciated bacterial infections[J]. Clin Pharmacol Ther, 2007, 82: 204-209.

共引文献300

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部